RegulationPriority Review (US), Breakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Conditional marketing approval (EU), Conditional marketing approval (GB)

Structure

Molecular FormulaC32H35ClFN7O2

InChIKeyPEMUGDMSUDYLHU-ZEQRLZLVSA-N

CAS Registry2326521-71-3

Clinical Trials associated with Adagrasib

NCT06412198 / Not yet recruitingPhase 1/2IIT

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Start Date30 Nov 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06248606 / RecruitingPhase 2

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

Start Date01 May 2024

Sponsor / Collaborator

Hoosier Cancer Research Network

[+2]

NCT05853575 / RecruitingPhase 2

A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Start Date01 Feb 2024

Sponsor / Collaborator

Mirati Therapeutics, Inc.

100 Clinical Results associated with Adagrasib

100 Translational Medicine associated with Adagrasib

100 Patents (Medical) associated with Adagrasib

128

Literatures (Medical) associated with Adagrasib

01 Mar 2024·Bioorganic chemistry

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Review

Author: Shang, Yanguo ; Wang, Jinxin ; Hao, Qingjing ; Shen, Tao ; Fu, Shengnan ; Ying, Hanjie

KRAS is the most frequently mutated oncogene and drives the development and progression of malignancies, most notably non-small cell lung cancer (NSCLS), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). However, KRAS proteins have maintained the reputation of being "undruggable" due to the lack of suitable deep pockets on its surface. One major milestone for KRAS inhibition was the discovery of the covalent inhibitors bond to the allosteric switch-II pocket of the KRAS^G12C protein. To date, the FDA has approved two KRAS^G12C inhibitors, sotorasib and adagrasib, for the treatment of patients with KRAS^G12C-driven cancers. Researchers have paid close attention to the development of inhibitors for other KRAS mutations and upstream regulatory factors. The KRAS targeted drug discovery has entered a state of rapid development. This article has aimed to present the current state of the art of drug development in the KRAS field. We systematically summarize recent advances in the discovery and optimization processes of direct KRAS inhibitors (including KRAS^G12C, KRAS^G12D, KRAS^G12A and KRAS^G12R inhibitors), indirect KRAS inhibitors (SOS1 and SHP2 inhibitors), pan-KRAS inhibitors, as well as proteolysis-targetingchimeras degrades and molecular chaperone modulators from the perspective of medicinal chemistry. We also discuss the current challenges and opportunities of KRAS inhibition and hope to shed light on future KRAS drug discovery.

01 Feb 2024·Pharmacological research

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis

Review

Author: Gao, Yi-Bo ; He, Jie ; Chen, Qi-An ; Zhou, Xiao-Xiang ; Cao, Zheng ; Lin, Wei-Hao ; Feng, Xiao-Li

OBJECTIVE:

To assess the efficacy and safety of FDA-approved KRAS^G12C inhibitors in patients with KRAS^G12C-mutated solid tumors.

METHODS:

We searched PubMed, EMBASE, Cochrane Library, and major international conferences for clinical trials published in English up to March 6, 2023. Clinical trials investigating sotorasib or adagrasib and reporting the clinical outcomes of the objective response rate (ORR), disease control rate (DCR), or incidence rate of grade ≥ 3 adverse events (AEs) were eligible. The primary endpoint was the ORR. Secondary endpoints included the DCR, incidence rate of grade ≥ 3 AEs, and odds ratio (OR) of the ORR between patients with or without co-mutation. The Random-effects model was applied for the outcomes of interest.

RESULTS:

18 studies with 1224 patients were included in this meta-analysis. The pooled ORR, DCR, and incidence rate of grade ≥ 3 AEs were 31 % (95 % CI, 25-37 %), 86 % (95 % CI, 82-89 %), and 29 % (95 % CI, 23-36 %), respectively. KRAS^G12C-mutated NSCLC patients with a co-mutation of KEAP1 exhibited a worse ORR than those with wild-type KEAP1 (OR: 0.35, 95 % CI: 0.16-0.77).

CONCLUSIONS:

This study provided a comprehensive understanding of the efficacy and safety of KRAS^G12C inhibitors in treating solid tumors and identified KEAP1 mutation as a potential predictive biomarker of inferior response in patients treated with KRAS^G12C inhibitors. These findings may assist in the design of future clinical trials for identifying populations that may benefit from KRAS^G12C inhibitor treatment.

01 Jan 2024·Current medicinal chemistry

First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRAS^G12C Mutation.

Article

Author: De, Surya K

Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS^G12C. It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS^G12C mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.

300

News (Medical) associated with Adagrasib

24 Jun 2024

·www.fiercepharma.com

BMS, Mirati's Krazati cements lead over Amgen's Lumakras with FDA approval in colorectal cancer

Aside from moving into a second indication to Lumakras’ one, Krazati further cemented its lead in the KRAS race this past March when BMS unveiled positive confirmatory results from the late-stage KRYSTAL-12 study in lung cancer. Despite coming to market second, Bristol Myers Squibb’s Mirati Therapeutics-inherited cancer med Krazati has gained the lead on its Amgen rival Lumakras in a heated KRAS race. Late Friday, the U.S. FDA granted an accelerated approval for BMS’ KRAS inhibitor Krazati plus Eli Lilly’s Erbitux (cetuximab) to treat certain chemotherapy-experienced adults with KRAS-mutated locally advanced or metastatic colorectal cancer (CRC). Given that the approval is accelerated, BMS may have to further prove Krazati’s merit in CRC in a confirmatory trial to keep hold of the green light. The new nod comes after Krazati’s initial approval in previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC) in Dec. 2022. Krazati, also known as adagrasib, was the second KRAS-targeting drug to hit the U.S. market behind Lumakras, which snagged its initial approval in NSCLC in May 2021. BMS got its hands on Krazati when it agreed to buy out Mirati for around $4.8 billion last fall. Bristol closed the transaction in late January. CRC with a KRAS G12C mutation occurs in approximately 3% to 4% of colorectal cancer patients and has historically proven difficult to treat, according to Rona Yaeger, M.D., gastrointestinal oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center. The FDA based its approval on early results from Krazati’s 94-patient, phase 1/2 KRYSTAL-1 open-label study, in which the drug was administered in 600mg tablets twice a day along with Erbitux either weekly or biweekly, the FDA explained in a separate release. In the trial, the Krazati combo reached a confirmed objective response rate (ORR) of 34%--meeting its primary endpoint—and charted a median duration of response (DOR) of 5.8 months. Thirty-one percent of patients who responded to Krazati had a DOR of at least half-a-year, the FDA noted. Current late-line standard-of-care medicines in CRC yield limited objective response rates of around 1% to 6% after progression on chemotherapy, BMS pointed out. Aside from moving into a second indication to Lumakras’ one, Krazati further cemented its lead in the KRAS race this past March when BMS unveiled confirmatory results from the late-stage KRYSTAL-12 study that found the med significantly reduced the risk of tumor progression or death versus chemotherapy in certain NSCLC patients. Krazati’s confirmatory win marked another blow to Lumakras after Amgen recently applied for a full approval of its rival KRAS inhibitor leveraging progression-free survival data from the phase 3 CodeBreaK 200 trial. Problem was, the FDA figured the study’s results couldn’t be reliably interpreted, and a group of external advisers agreed. Despite this, the FDA has let Lumakras stay on the market while Amgen runs another confirmatory study. The California-based company expects that to be done no later than Feb. 2028. Meanwhile, Amgen is also gunning for a Lumakras approval in CRC. The company in October reported results from its phase 3 CodeBreaK 300 trial showing that 960mg Lumakras plus Vectibix extended patients' median progression-free survival to 5.6 months versus 2.2 months for standard treatments in chemo-refractory KRAS G12C colorectal cancer. Krazati, during its first earnings quarter under BMS’ wing, snared $21 million over the first three months of 2024.

Clinical ResultDrug ApprovalPhase 3Acquisition

24 Jun 2024

·pmlive.com

Bristol Myers Squibb’s Krazati granted FDA accelerated approval in colorectal cancer

Bristol Myers Squibb’s (BMS) KRAS inhibitor Krazati (adagrasib) has been granted accelerated approval by the US Food and Drug Administration (FDA) as part of a combination treatment for a subset of colorectal cancer (CRC) patients. The drug has been authorised for use alongside cetuximab as a targeted treatment option for adults with locally advanced or metastatic cases of the disease who are carrying the KRASG12C mutation, which occurs in approximately up to 4% of CRC patients and has historically been challenging to treat. Eligible patients will also have received prior treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. CRC is the third most commonly diagnosed cancer globally, with more than 106,000 new cases of the disease expected to be diagnosed in the US this year. Taken orally twice daily, Krazati is a small-molecule inhibitor of KRASG12C and is already approved in the US to treat specific cases of non-small cell cancer (NSCLC). The FDA’s latest decision was supported by positive results from cohorts of the phase 1/2 KRYSTAL-1 study, in which Krazati plus cetuximab demonstrated a confirmed objective response rate of 34% and a median duration of response of 5.8 months. As per the regulator’s accelerated approval pathway, continued authorisation for the drug in this indication may be contingent on results from a confirmatory trial. Wendy Short Bartie, senior vice president, US oncology and haematology at BMS, described the new approval as “an important milestone” for the company and the patients it serves. “We are proud to make Krazati – the first KRASG12C inhibitor to be FDA approved beyond NSCLC – available to CRC patients, and look forward to further evaluating Krazati through our ongoing development programme,” she said. BMS gained access to Krazati through its recent $5.8bn acquisition of Mirati Therapeutics. The deal, which closed in January, also included multiple other targeted oncology assets, such as MRTX1719, which BMS said had shown “encouraging” early efficacy data across several tumour types, including NSCLC and melanoma. Giovanni Caforio, the then chief executive officer at BMS, said at the time of the buyout announcement in October: “We are excited to add these assets to our portfolio and to accelerate their development as we seek to deliver more treatments for cancer patients.”

Drug ApprovalAcquisitionClinical ResultAccelerated Approval

22 Jun 2024

·pipelinereview.com

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients with locally advanced or metastatic CRC harboring a KRAS G12C mutation 1 Second FDA approval for KRAZATI – reinforcing its potential across tumor types PRINCETON, NJ, USA I June 21, 2024 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI ® (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRAS G12C -mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) results. Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial. “CRC with a KRAS G12C mutation occurs in approximately 3-4% of CRC patients and has historically been challenging to treat,” 2 said Rona Yaeger, MD, Gastrointestinal Oncologist & Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center. “The FDA approval of KRAZATI combined with cetuximab now provides a new treatment option to these patients when their tumors do not respond well to prior therapies.” The approval is based on results from cohorts of the Phase 1/2 KRYSTAL-1 open-label study which evaluated KRAZATI (600 mg tablets administered orally twice daily) in combination with cetuximab in 94 patients with heavily pretreated CRC harboring a KRAS G12C mutation. The study met its primary endpoint, with a confirmed ORR of 34% (n=94, 95% CI: 25-45) for KRAZATI with cetuximab, all of which were partial responses. The median DOR, one of the secondary endpoints, was 5.8 months (95% CI: 4.2-7.6). 1 Current late-line standard of care options result in limited response rates (ORR 1-6%) after progression on chemotherapy ± VEGF/VEGFR inhibitors. 3,4 KRAZATI is associated with the following Warnings & Precautions: Gastrointestinal adverse reactions including diarrhea, nausea, and vomiting, QTc interval prolongation, hepatotoxicity, and interstitial lung disease (ILD)/pneumonitis. 1 Please see Important Safety Information below. “Today’s approval of KRAZATI in CRC is the second in the U.S. for this therapy and the first for BMS’ recently expanded oncology portfolio. This is an important milestone for BMS and the patients we serve as we deliver on our commitment to provide innovative medicines for cancer,” said Wendy Short Bartie, senior vice president, U.S. Oncology and Hematology at Bristol Myers Squibb. “We are proud to make KRAZATI – the first KRAS G12C inhibitor to be FDA approved beyond non-small cell lung cancer – available to CRC patients, and look forward to further evaluating KRAZATI through our ongoing development program.” In 2022, the FDA granted breakthrough therapy designation for KRAZATI in combination with cetuximab for patients with KRAS G12C -mutated advanced CRC whose cancer has progressed following prior treatment with certain chemotherapy and an anti-VEGF therapy. KRAZATI is an irreversible inhibitor of KRAS G12C with a long half-life (23 hours), dose-dependent pharmacokinetics (PK), and central nervous system (CNS) penetration, which, in combination with cetuximab may enhance inhibition of KRAS-dependent signaling or overcome adaptive feedback. The company partnered with QIAGEN to develop a tissue-based companion diagnostic (CDx) for KRAZATI that is now available. KRAZATI is a registered trademark of Mirati Therapeutics, Inc., a Bristol Myers Squibb company. About KRYSTAL-1 KRYSTAL-1 is an open-label, multicenter, multiple expansion cohort Phase 1/2 trial to determine the safety and efficacy of KRAZATI in patients with advanced colorectal cancer (CRC) that harbor a KRAS G12C mutation. The primary endpoint for the Phase 2 cohort of the KRYSTAL-1 study was objective response rate (ORR). Secondary endpoints included duration of response (DOR). The KRYSTAL-1 study was funded by Mirati Therapeutics, Inc., a Bristol Myers Squibb company. Select Safety Profile from KRYSTAL-1 The safety profile for KRAZATI plus cetuximab was evaluated in patients with KRAS G12C -mutated, locally advanced or metastatic CRC, and is consistent with previous reports and known safety profile of each drug individually. Serious adverse reactions occurred in 30% of 94 patients who received KRAZATI in combination with cetuximab. The most common adverse reactions (≥20%) were rash, nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, headache, dry skin, abdominal pain, decreased appetite, edema, anemia, dizziness, cough, constipation, and peripheral neuropathy. 1 About Colorectal Cancer Colorectal cancer (CRC) is cancer that develops in the colon or the rectum, which are part of the body’s digestive, or gastrointestinal, system. 5 CRC is the third most commonly diagnosed cancer in the world. 6 In 2024, it is estimated that there will be approximately 106,590 new cases of the disease in the U.S.; it is the second leading cause of cancer-related deaths in the U.S. among men and women combined. 7 KRAS is the most frequently mutated oncogene in human cancer and is one that drives oncogenesis in up to 50% of patients with CRC. 2 The KRAS G12C mutation occurs in approximately 3-4% of CRC cases. 2 About KRAZATI ® (adagrasib) KRAZATI (adagrasib) is a highly selective and potent oral small-molecule inhibitor of KRAS G12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRAS G12 C -mutated cancers, as the KRAS G12C protein regenerates every 24-48 hours. 8 KRAS G12C mutations act as oncogenic drivers and occur in approximately 14% of non-small cell lung cancer (NSCLC; adenocarcinoma) and 3% of several other cancers. 9,10 In 2022, KRAZATI was granted accelerated approval for treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial. KRAZATI continues to be evaluated as a monotherapy and in combination with other anti-cancer therapies in patients with advanced KRAS G12C -mutated solid tumors, including NSCLC and CRC. Please see U.S. Full Prescribing Information for KRAZATI . INDICATIONS KRAZATI in combination with cetuximab is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. KRAZATI , as a single agent, is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. Please see U.S. Full Prescribing Information for KRAZATI . Bristol Myers Squibb: Creating a Better Future for People with Cancer Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position the company to approach cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, please visit BMS.com or follow us on LinkedIn , X (formerly Twitter), YouTube , Facebook , and Instagram . 1 KRAZATI. Prescribing Information. Princeton, NJ. Mirati Therapeutics, Inc., a Bristol Myers Squibb company; 2024. 2 Yaeger, R., Weiss, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. New England Journal of Medicine . 2023;388(1), 44–54. https://doi.org/10.1056/nejmoa2212419 3 Prager, G., et al. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. New England Journal of Medicine . 2023 May 4;388(18). https://www.nejm.org/doi/full/10.1056/NEJMoa2214963 4 Grothey, A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet . https://pubmed.ncbi.nlm.nih.gov/23177514/ 5 What is colorectal cancer? American Cancer Society. (n.d.) https://www.cancer.org/cancer/colon-rectal-cancer/about/what-is-colorectal-cancer.html 6 Globocan 2020, World https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf 7 Colorectal cancer statistics: How common is colorectal cancer? American Cancer Society. (n.d.). https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html 8 Hallin J, Engstrom LD, Hargis L, et al. The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov . 2020;10(1):54-71 9 Campbell et al, Nature Genetics 2016 “Distinct patterns of somatic genome alterations in lung adenocarcinomas 10 Nassar, A., et al. Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type. New England Journal of Medicine, 384:185-187. https://doi.org/10.1056/nejmc2030638 SOURCE: Bristol Myers Squibb

Drug ApprovalClinical ResultPhase 3Accelerated ApprovalBreakthrough Therapy

100 Deals associated with Adagrasib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
KRAS G12C mutant Colorectal Cancer	US	Mirati Therapeutics, Inc.	21 Jun 2024
KRAS G12C mutant Non-small Cell Lung Cancer	US	Mirati Therapeutics, Inc.	12 Dec 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Colorectal Adenocarcinoma	Phase 3	US	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	AR	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	AU	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	AT	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	BE	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	BR	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	CA	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	CO	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	CZ	Mirati Therapeutics, Inc.	15 Mar 2021
Advanced Colorectal Adenocarcinoma	Phase 3	DK	Mirati Therapeutics, Inc.	15 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03785249 (KRYSTAL-1, FDA_CDER) Manual	Phase 2	KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C	112	Adagrasib	ykpgpemhxv(jolloszvru) = stwgqrhtmj ihjprgwmts (nsrsnrdbzi, 34 - 53) View more	Positive	21 Jun 2024
NCT03785249 (KRYSTAL-1, FDA_CDER) Manual	Phase 2	KRAS G12C mutant Colorectal Cancer KRAS G12C	94	Adagrasib + cetuximab	xtelsnehdj(dbffqpgbvh) = gmobwvnarx zespwlnkrw (prumwxmmik, 25 - 45) View more	Positive	21 Jun 2024
NCT04685135 (KRYSTAL-12, ASCO2024) Manual	Phase 3	KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C	453	Adagrasib (ADA)	mzdfyauhhl(cvlneljlyo) = tvzhrquhwb pjwcpbugiq (qjeytytkwi ) View more	Positive	02 Jun 2024
				Docetaxel (DOCE)	mzdfyauhhl(cvlneljlyo) = teukyuknny pjwcpbugiq (qjeytytkwi ) View more
KRYSTAL-1 (Literature) Manual	Phase 1/2	Metastatic Colorectal Carcinoma KRAS G12C	94	Adagrasib plus Cetuximab	jijjgpewgs(nkzvgdsbdi) = ujmiobkwyd ztdvzifyrd (pjacikgkuj ) View more	Positive	08 Apr 2024
NCT04685135 (KRYSTAL-12, Corporate Publications) Manual	Phase 3	KRAS G12C mutant Non-small Cell Lung Cancer Second line	43	KRAZATI	rwvtsshyvx(ghrocrmcgh) = met zhfltfnxue (vfcmpaibfx ) Met View more	Positive	28 Mar 2024
				standard-of-care chemotherapy
KRYSTAL-1 study (NEWS) Manual	Clinical	Colorectal Cancer KRAS	-	Adagrasib	jeaqsryjyo(upvlocphzk) = rpxmzndhfb rxnxtrqsno (oquzwtzknw ) View more	Positive	08 Jan 2024
				Adagrasib + Cetuximab	jeaqsryjyo(upvlocphzk) = mvctwsmwne rxnxtrqsno (oquzwtzknw ) View more
ESMO2023	Not Applicable	KRAS G12C mutation Solid Tumors	-	Combination of MRTX1257 and RT	mbyprcswhx(harencncda) = tjmyatqunw rozbqilktj (zotgqdnqgk )	-	21 Oct 2023
NCT04613596 (KRYSTAL-7, ESMO2023) Manual	Phase 2	KRAS G12C mutant Non-small Cell Lung Cancer First line KRAS G12C	148	Adagrasib 400 mg + Pembrolizumab 200 mg	uqdtcctamc(lkfkewimwi) = zqnpybfkrn lazmjubmzg (mectfdqxip ) View more	Positive	20 Oct 2023
				Adagrasib 400 mg + Pembrolizumab 200 mg (PD-L1 ≥50%)	uqdtcctamc(lkfkewimwi) = xgwnqoojbe lazmjubmzg (mectfdqxip ) View more
NCT03785249 (KRYSTAL-1, WCLC2023) Manual	Phase 1/2	KRAS G12C mutant Non-small Cell Lung Cancer KRASG12C mutation	132	Adagrasib 600 mg BID	xdwtyftemr(tfnqktfldx) = tyrnecppqu eqdphjjopd (aplgsfzmgs ) View more	Positive	10 Sep 2023
				Adagrasib 600 mg BID (KEAP1 co-mutations)	nfgzykbhbb(xyxdcfdgkg) = ecfotyqohi tydcgwdtrn (iextjudoqc, 3.6 - 9.2)
NCT03785249 (KRYSTAL-1, Pubmed)	Phase 1/2	Brain metastases	-	Adagrasib 600 mg	tnmsgaolkt(avwgyifvjy) = The most common CNS-specific TRAEs included dysgeusia (24%) and dizziness (20%) ergaruadkj (qjuzcsqxzd ) View more	-	16 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Adagrasib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation